IR@PKUHSC  > 北京大学临床肿瘤学院  > 病理科
学科主题临床医学
Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma
Ding, Ning1; Li, Xitao2; Shi, Yunfei3; Ping, Lingyan1; Wu, Lina4; Fu, Kai5; Feng, Lixia1; Zheng, Xiaohui1; Song, Yuqin1; Pan, Zhengying2; Zhu, Jun1
关键词BCR signaling Btk irreversible inhibitor targeted therapy B-cell lymphoma
刊名ONCOTARGET
2015-06-20
6期:17页:15122-15136
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology ; Cell Biology
研究领域[WOS]Oncology ; Cell Biology
关键词[WOS]CHRONIC LYMPHOCYTIC-LEUKEMIA ; TYROSINE KINASE INHIBITOR ; IN-VIVO ; THERAPEUTIC TARGET ; RECEPTOR ; PCI-32765 ; IBRUTINIB ; PATHWAY ; MALIGNANCIES ; ACTIVATION
英文摘要

The B-cell receptor (BCR) signaling pathway has gained significant attention as a therapeutic target in B-cell malignancies. Recently, several drugs that target the BCR signaling pathway, especially the Btk inhibitor ibrutinib, have demonstrated notable therapeutic effects in relapsed/refractory patients, which indicates that pharmacological inhibition of BCR pathway holds promise in B-cell lymphoma treatment. Here we present a novel covalent irreversible Btk inhibitor PLS-123 with more potent anti-proliferative activity compared with ibrutinib in multiple cellular and in vivo models through effective apoptosis induction and dual-action inhibitory mode of Btk activation. The phosphorylation of BCR downstream activating AKT/mTOR and MAPK signal pathways was also more significantly reduced after treatment with PLS-123 than ibrutinib. Gene expression profile analysis further suggested that the different selectivity profile of PLS-123 led to significant downregulation of oncogenic gene PTPN11 expression, which might also offer new opportunities beyond what ibrutinib has achieved. In addition, PLS-123 dose-dependently attenuated BCR- and chemokine-mediated lymphoma cell adhesion and migration. Taken together, Btk inhibitor PLS-123 suggested a new direction to pharmacologically modulate Btk function and develop novel therapeutic drug for B-cell lymphoma treatment.

语种英语
WOS记录号WOS:000359010700037
项目编号81470368 ; 81201873 ; 2013CB910704 ; 2011CB504303 ; 7132050 ; JCYJ20140509093817688 ; 81373270
资助机构NSFC ; 973 program ; Beijing Natural Science Foundation ; Shenzhen Science and Technology Innovation Committee ; National Natural Science Foundation of China ; "985" Basic Research Fund from Peking University
引用统计
被引频次:7[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/64721
专题北京大学临床肿瘤学院_病理科
北京大学临床肿瘤学院_淋巴肿瘤内科
北京大学临床肿瘤学院_中心实验室
作者单位1.Peking Univ, Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Minist Educ,Dept Lymphoma, Beijing 100871, Peoples R China
2.Peking Univ, Shenzhen Grad Sch, Sch Chem Biol & Biotechnol, Key Lab Chem Genom, Shenzhen, Peoples R China
3.Peking Univ, Canc Hosp & Inst, Dept Pathol, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100871, Peoples R China
4.Peking Univ, Canc Hosp & Inst, Cent Lab, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100871, Peoples R China
5.Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE USA
推荐引用方式
GB/T 7714
Ding, Ning,Li, Xitao,Shi, Yunfei,et al. Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma[J]. ONCOTARGET,2015,6(17):15122-15136.
APA Ding, Ning.,Li, Xitao.,Shi, Yunfei.,Ping, Lingyan.,Wu, Lina.,...&Zhu, Jun.(2015).Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma.ONCOTARGET,6(17),15122-15136.
MLA Ding, Ning,et al."Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma".ONCOTARGET 6.17(2015):15122-15136.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Ding, Ning]的文章
[Li, Xitao]的文章
[Shi, Yunfei]的文章
百度学术
百度学术中相似的文章
[Ding, Ning]的文章
[Li, Xitao]的文章
[Shi, Yunfei]的文章
必应学术
必应学术中相似的文章
[Ding, Ning]的文章
[Li, Xitao]的文章
[Shi, Yunfei]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。